On Thursday, JPMorgan reiterated a neutral rating on Alkermes (NASDAQ:ALKS) with a price target of $32.00. The firm's analyst highlighted Alkermes' continued investment in its orexin portfolio following the company's Orexin Portfolio Strategy Review. Management's decision to develop ALKS-2680 for idiopathic hypersomnia (IH) was among the key points discussed, alongside pre-clinical data suggesting potential applications in attention, impulsivity, and mood disorders.
Alkermes is currently conducting two phase II studies for narcolepsy types 1 and 2, known as VIBRANCE-1 and VIBRANCE-2, respectively. Results from these studies are anticipated in the second half of 2025. Additionally, a phase II study for IH, named VIBRANCE-3, is expected to commence next year. Expert feedback from the event indicated that ALKS-2680 would likely experience rapid adoption within the NT1 patient group, now estimated to be around 30% of those with narcolepsy.
The company also discussed its efforts to explore the orexin mechanism for other neurological and psychiatric conditions, as well as selected rare diseases. Plans are in place to introduce additional orexin-2 agonist molecules into clinical trials in 2025, which may be aimed at treating ADHD and mood disorders.
JPMorgan expressed incremental encouragement based on these updates, seeing potential for Alkermes as the company approaches the release of phase II topline data for NT1 and NT2 in 2025.
In other recent news, Alkermes has seen significant developments in its drug research and financial performance. The company's Q2 2024 revenue reached $399 million, primarily driven by robust sales of proprietary products Lybalvi and Aristada. Analyst firms Baird and H.C. Wainwright have elevated their share targets for Alkermes, reflecting an optimistic outlook on the company's performance.
Alkermes has initiated the Vibrance-2 phase 2 clinical trial to evaluate the safety and efficacy of its investigational drug ALKS 2680 for adults with narcolepsy type 2. Mizuho Securities, Piper Sandler, and Jefferies have maintained their favorable ratings on Alkermes, citing the potential of ALKS-2680 as a leading treatment for narcolepsy.
Furthermore, Alkermes is considering the further development of ALKS-2680 for idiopathic hypersomnia (IH), based on the unmet need and positive feedback from patient groups and clinicians following Phase 1b data. The company is also exploring the potential of OX2 in other indications, such as neurodegenerative and neurodevelopmental diseases, where disrupted sleep is a clinical feature.
InvestingPro Insights
Alkermes' strategic focus on its orexin portfolio, as highlighted in the article, is reflected in its financial performance and market position. According to InvestingPro data, the company boasts a market capitalization of $4.38 billion and a price-to-earnings ratio of 15.35, suggesting a relatively moderate valuation considering its growth prospects.
Two key InvestingPro Tips are particularly relevant to Alkermes' current situation. First, management has been aggressively buying back shares, which could indicate confidence in the company's future and potentially support the stock price. Second, Alkermes holds more cash than debt on its balance sheet, providing financial flexibility to fund its ongoing research and development efforts, including the orexin portfolio and upcoming clinical trials.
The company's strong financial position is further evidenced by its gross profit margin of 83.31% for the last twelve months as of Q2 2024, indicating efficient operations and potential for reinvestment in research. Additionally, with a return on assets of 13.14%, Alkermes demonstrates effective use of its assets in generating profits.
For investors interested in a deeper analysis, InvestingPro offers 8 additional tips that could provide further insights into Alkermes' financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.